PHOTO GALLERY | 'How to help real people': Pitt-Johnstown professors move forward with tick repellant business

Back in 2019, University of Pittsburgh at Johnstown biology professor Jill Henning started developing and sharing her idea of ...
Medscape

When Lab Reference Values May Mislead Clinicians

Laboratory reference ranges reflect methods, populations, and policies, and experienced clinicians interpret them in context rather than applying fixed cutoffs theoretically.
The Financial Express

Anaemia isn’t just iron deficiency, then what causes low haemoglobin? Apollo Hospital’s Dr Rakesh Gupta explains

Anaemia isn't just about iron deficiency. Learn about the roles of Vitamin B12, chronic illness, and gut health in blood health, plus expert advice on diagnosis, warning signs, and the best diet for ...
KOMU 8

Carbon monoxide poisoning can be deadly. Experts say prevention is simple

Tips from Columbia Fire Chief Brian Schaeffer and a brain injury specialist on how to prevent and recognize carbon monoxide ...

Alector, Inc. (ALEC) Presents at TD Cowen 46th Annual Health Care Conference Transcript

TD Cowen 46th Annual Health Care Conference March 3, 2026 3:10 PM ESTCompany ParticipantsEric BrownGiacomo Salvadore - Chief ...

'Checks all the boxes': Pitt-Johnstown professors form business to continue development of tick repellant

University of Pittsburgh at Johnstown professors Manisha Nigam, Matt Tracey and Jill Henning have formed a business, Adventure Bioscience, to further develop and potentially ...

NovelMed Therapeutics Announces Regulatory Clearance for Subcutaneous Ruxoprubart and Reports Positive Phase II Intravenous Monotherapy Results in PNH

Precision Bb Targeting, Robust Efficacy, Transfusion Independence, Excellent Safety in Phase II PNH Study, and Subcutaneous Administration The 12-16-week open-label study evaluated Ruxoprubart as ...

Feds award $22 million to Penn spinout Linnaeus Therapeutics to advance anti-aging drug

University of Pennsylvania spinout Linnaeus Therapeutics has secured $22 million in federal funding to test whether its once-a-day pill can help Americans reap the benefits of estrogen without ...
Medindia

Johnson & Johnson seeks FDA approval of IMAAVY® (nipocalimab-aahu) as the first-ever FDA-approved treatment for warm autoimmune hemolytic anemia (wAIHA)

Tranekær S, Hansen DL, Frederiksen H. Epidemiology of secondary warm autoimmune haemolytic anaemia-A systematic review and meta-analysis. J Clin Med . 2021 ...
The Malaysian Reserve

Citius Oncology Announces Preliminary Topline Phase 1 Data from Study of LYMPHIR™ (E7777) Dosing Prior to Commercial CAR‑T Therapy in High‑Risk Diffuse Large B‑Cell ...

Topline data of investigator‑initiated study at the University of Minnesota and City of Hope demonstrates 86% overall response rate (OR), including 57% ...

Citius Oncology, Inc.: Citius Oncology Announces Positive Topline Results from Investigator-Initiated Phase 1 Study of LYMPHIR in Combination with Pembrolizumab in Relapsed or ...

Study data from patients with relapsed or refractory gynecologic cancers signals the potential of LYMPHIR to augment immune checkpoint inhibitor efficacy Topline data ...

Keros Therapeutics Touts Rinvat­ercept DMD Trial Start, Eyes ALS Phase II Talks at Oppenheimer Conference

CEO Jasbir Seehra outlined the company’s development priorities and partnership plans during a presentation at Oppenheimer’s 36th Annual Healthcare Life Sciences conference, highlighting plans to init ...